Cue Biopharma Statistics
Total Valuation
Cue Biopharma has a market cap or net worth of $76.86 million. The enterprise value is $40.20 million.
| Market Cap | 76.86M |
| Enterprise Value | 40.20M |
Important Dates
The last earnings date was Monday, April 8, 2024, after market close.
| Earnings Date | Apr 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Cue Biopharma has 48.64 million shares outstanding. The number of shares has increased by 28.35% in one year.
| Shares Outstanding | 48.64M |
| Shares Change (YoY) | +28.35% |
| Shares Change (QoQ) | +1.81% |
| Owned by Insiders (%) | 2.97% |
| Owned by Institutions (%) | 32.92% |
| Float | 45.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.00 |
| Forward PS | 19.02 |
| PB Ratio | 2.07 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.32 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.01, with a Debt / Equity ratio of 0.40.
| Current Ratio | 3.01 |
| Quick Ratio | 3.11 |
| Debt / Equity | 0.40 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -39.75 |
Financial Efficiency
Return on equity (ROE) is -112.30% and return on invested capital (ROIC) is -100.41%.
| Return on Equity (ROE) | -112.30% |
| Return on Assets (ROA) | -71.10% |
| Return on Capital (ROIC) | -100.41% |
| Revenue Per Employee | $103,585 |
| Profits Per Employee | -$957,226 |
| Employee Count | 53 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -52.34% in the last 52 weeks. The beta is 2.01, so Cue Biopharma's price volatility has been higher than the market average.
| Beta (1Y) | 2.01 |
| 52-Week Price Change | -52.34% |
| 50-Day Moving Average | 1.98 |
| 200-Day Moving Average | 2.60 |
| Relative Strength Index (RSI) | 38.28 |
| Average Volume (30 Days) | 258,929 |
Short Selling Information
The latest short interest is 4.20 million, so 8.64% of the outstanding shares have been sold short.
| Short Interest | 4.20M |
| Short Previous Month | 4.12M |
| Short % of Shares Out | 8.64% |
| Short % of Float | 9.26% |
| Short Ratio (days to cover) | 17.76 |
Income Statement
In the last 12 months, Cue Biopharma had revenue of $5.49 million and -$50.73 million in losses. Loss per share was -$1.11.
| Revenue | 5.49M |
| Gross Profit | 5.49M |
| Operating Income | -51.99M |
| Pretax Income | -50.73M |
| Net Income | -50.73M |
| EBITDA | -46.05M |
| EBIT | -49.49M |
| Loss Per Share | -$1.11 |
Balance Sheet
The company has $51.36 million in cash and $14.70 million in debt, giving a net cash position of $36.66 million or $0.75 per share.
| Cash & Cash Equivalents | 51.36M |
| Total Debt | 14.70M |
| Net Cash | 36.66M |
| Net Cash Per Share | $0.75 |
| Equity / Book Value | 37.09M |
| Book Value Per Share | 0.76 |
| Working Capital | 34.37M |
Cash Flow
In the last 12 months, operating cash flow was -$39.96 million and capital expenditures $2,000, giving a free cash flow of -$39.96 million.
| Operating Cash Flow | -39.96M |
| Capital Expenditures | 2,000 |
| Free Cash Flow | -39.96M |
| FCF Per Share | -$0.87 |
Margins
Gross margin is 100.00%, with operating and profit margins of -947.03% and -924.10%.
| Gross Margin | 100.00% |
| Operating Margin | -947.03% |
| Pretax Margin | -924.10% |
| Profit Margin | -924.10% |
| EBITDA Margin | -838.83% |
| EBIT Margin | -901.42% |
| FCF Margin | -727.85% |
Dividends & Yields
Cue Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -28.35% |
| Shareholder Yield | -28.35% |
| Earnings Yield | -66.01% |
| FCF Yield | -51.99% |
Analyst Forecast
The average price target for Cue Biopharma is $9.50, which is 501.27% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.50 |
| Price Target Difference | 501.27% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 102.16% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Cue Biopharma has an Altman Z-Score of -6.86 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.86 |
| Piotroski F-Score | 3 |